Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | PRKX | P51817 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049381 | 0.89 | ROCK2 (0.53) | SMN1; SMN2HDAC1ROCK1ROCK2CYP3A4 | |
| SCHEMBL5046663 | 0.89 | L3MBTL1 (0.45) | SMN1; SMN2HDAC1L3MBTL1KDM4EBCHE | |
| SCHEMBL5046403 | 0.86 | KDM4E (0.51) | SMN1; SMN2HDAC1ROCK1ROCK2CYP3A4 | |
| SCHEMBL5048180 | 0.86 | ADRB2 (0.44) | SMN1; SMN2HDAC1ROCK1ROCK2CYP3A4 | |
| SCHEMBL5048113 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2HDAC1ROCK1ROCK2CYP3A4 | |
| SCHEMBL5050279 | 0.85 | KDM4E (0.46) | SMN1; SMN2HDAC1ROCK1ROCK2CYP3A4 | |
| SCHEMBL5049384 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2HDAC1KDM4EBCHEMEN1 | |
| SCHEMBL15876016 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2HDAC1BCHEMEN1KMT2A | |
| SCHEMBL5046821 | 0.81 | PTGER2 (0.48) | SMN1; SMN2HDAC1KDM4EHDAC3HDAC2 | |
| SCHEMBL5046565 | 0.80 | MAPT (0.46) | SMN1; SMN2CYP3A4CYP2D6L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | SMN1; SMN2 3228/4885HDAC1 3221/4885ROCK1 405/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | SMN1; SMN2 3405/4885HDAC1 4747/4885ROCK1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.